GlaxoSmithKline (GSK) gained access to BioWa's Potelligent® technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.
The agreement grants GSK nonexclusive rights to research and develop antibodies based on this platform for an undisclosed number of targets. In return, BioWa will receive an upfront payment and license fees.
Potelligent improves potency and efficacy of antibody therapeutics by enhancing ADCC, according to BioWa. It reduces the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.